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Abstract
Background: The role of antibiotics in treating mild or moderate exacerbations in patients with acute chronic
obstructive pulmonary disease (COPD) is unclear. The aims were to: (i) describe patient characteristics associated
with acute exacerbations amongst a representative COPD population, (ii) explore the relationship between COPD
severity and outcomes amongst patients with exacerbations, and (iii) quantify variability by general practice in
prescribing of antibiotics for COPD exacerbations.
Method: A cohort of 62,747 patients with COPD was identified from primary care general practices (GP) in England,
and linked to hospital admission and death certificate data. Exacerbation cases were matched to three controls and
characteristics compared using conditional logistic regression. Outcomes were compared using incidence rates and
Cox regression, stratified by disease severity. Variability of prescribing at the GP level was evaluated graphically and
by using multilevel models.
Results: COPD severity was found to be associated with exacerbation and subsequent mortality (very severe vs.
mild, odds ratio for exacerbation 2.12 [95%CI 19.5–2.32]), hazard ratio for mortality 2.14 [95%CI 1.59–2.88]). Whilst
61% of exacerbation cases were prescribed antibiotics, this proportion varied considerably between GP practices
(interquartile range, 48–73%). This variation is greater than can be explained by patient characteristics alone.
Conclusions: There is significant variability between GP practices in the prescribing of antibiotics to COPD patients
experiencing exacerbations. Combined with a lack of evidence on the effects of treatment, this supports the need
and opportunity for a large scale pragmatic randomised trial of the prescribing of antibiotics for COPD patients
with exacerbations, in order to clarify their effectiveness and long term outcomes whilst ensuring the
representativeness of subjects.
Keywords: Chronic obstructive pulmonary disease, Disease exacerbation, Clinical practice variation, Anti-bacterial
agents, Primary health care, General practice
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive condition characterised by an obstructive pat-
tern of expiratory airflow limitation which can’t be fully
reversed. An estimated 3 million people have COPD in
the UK with associated annual healthcare costs of £800
million [1,2]. COPD patients frequently suffer acute ex-
acerbations of the disease, characterised by an increase
in dyspnoea, sputum volume or purulence. Exacerba-
tions are often bacterial in origin and antibiotic therapy
is appropriate [3]. However, exacerbations may also be
due to viral infections of the upper respiratory tract or
may be non-infective. The role of antibiotics in treating
mild or moderate acute exacerbation is unclear [4]. Most
randomised trials evaluating antibiotics for COPD were
restricted to patients hospitalised for acute exacerbations
[5]. Of the 11 studies included in a recent review only 2
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included patients from a GP setting, despite much
healthcare for COPD patients being administered in this
environment. Also, few of the studies provided details
on resource utilisation associated with exacerbations or
the effect of prescribing antibiotics on this utilisation [5].
Databases of electronic health records (EHR), such as
those managed by the Clinical Practice Research
Datalink (CPRD), provide the opportunity to conduct a
large pragmatic randomised trial evaluating effects of an-
tibiotics in patients with mild or moderate acute COPD
exacerbations [6]. Participants can be recruited at the
point of care and followed using routinely collected
EHR. A key requirement for pragmatic trials is that
‘usual conditions’ apply to the research setting [7,8]. The
selection and monitoring of patients should ideally
mimic the ‘real world’. The only difference should be the
random allocation of the interventions rather than the
investigators deciding how to treat patients. Such a trial
is currently being conducted within CPRD, and the
present study was initiated in order to provide back-
ground information about current medical practice and
outcomes of COPD exacerbations. The objectives were
to: (i) describe the patient characteristics associated with
acute exacerbations amongst a representative COPD
population, (ii) explore the relationship between COPD
severity and outcomes amongst patients with exacerba-
tions, and (iii) quantify variability by practice in prescrib-
ing of antibiotics for exacerbations.
Methods
This study used data from the UK General Practice Re-
search Database (GPRD), the foundation of the CPRD
primary care data. The database comprises computerised
medical records maintained by GPs. The data, prospect-
ively recorded since 1987, include demographics, pre-
scriptions, clinical events, preventive care, specialist
referrals, hospital admissions and major outcomes and
covers 8% of the UK population [9]. A recent review of
validation studies found that CPRD medical data were
generally high quality [10].
CPRD primary care patients have been linked to hos-
pital admission (Hospital Episode Statistics [HES]) and
death certificate data. The linkages are performed using
patients NHS numbers, dates of birth, sex and post-
codes. HES collect dates of admission and discharge and
main diagnoses, extracted from the medical records by
coding staff. The death certificates list the date and
causes of death. Linked data were available for 48% of
practices (309 of the 639 practices; only practices in
England willing to provide patient identifiers to the
Trusted Third Party were included), shown to be repre-
sentative of practices as a whole [11]. The study protocol
was approved by the CPRD Independent Scientific Ad-
visory Committee. All data was managed and analysed
using Stata version 11.2 (Copyright 2009 StataCorp LP,
Texas, USA).
Cohort 1: COPD population
The study population included patients aged ≥40 years
with a history of COPD in the clinical or referral files of
the primary care data (as defined by the Quality and
Outcomes Framework diagnostic Read codes [12]) who
were eligible for linkage. The population was restricted
to patients with at least nine months of active registra-
tion during 2005 to 2010, defined as the period between
(a) the maximum of the patient’s current registration
date and the practice “up-to-standard” date, and (b) the
minimum of the date at which the patient left the prac-
tice and the last CPRD collection date from that prac-
tice. A random date was selected within the active
registration period for each patient, ensuring at least six
months of prior registration, and three months of
follow-up during 2005 to 2010. This was done by first
calculating the available eligible follow-up time (i.e. the
time between the earliest date that the patient had six
months of prior registration and the latest date that the
patient had three months of follow-up). This was multi-
plied by a random number between zero and one and
the resulting value was added to the start date of the eli-
gible follow-up period. This date was used as the “index
date” at which patient characteristics were measured.
Cohort 2: exacerbation cases and controls
Within the study population, records of acute exacerba-
tions were identified on the basis of Read codes
(H312200: “Acute exacerbation of chronic obstructive
airways disease”, H3y1.00: “Chron obstruct pulmonary
dis wth acute exacerbation, unspec”) entered in the clin-
ical and referral files. These records may have been en-
tered prospectively or retrospectively (e.g. in the case of
a patient presenting at an A&E unit with exacerbation).
Individual exacerbation records were then grouped into
episodes. Records within 28 days of a previous exacerba-
tion record were considered to refer to the same epi-
sode. As such, the start of the episode was defined as the
first record with no other exacerbation records in the
previous 28 days and the end was defined as the last rec-
ord with no other exacerbation records in the following
28 days. If a patient had several exacerbation episodes,
one was randomly selected as the index event. Exacerba-
tion events were excluded if they did not fulfil the inclu-
sion criteria: (i) at least six months of prior registration
in the primary care records, (ii) at least six months of
prior coverage in HES, (iii) between 2005 and 2010, (iv)
after COPD diagnosis, (v) patient was aged ≥40, (vi)
prior to the end of primary care follow-up, (vii) prior to
the end of HES coverage. Patients did not require any
minimum amount of follow-up after the exacerbation.
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Each exacerbation case was matched by age (within
five years) and sex to up to three controls (patients not
suffering exacerbation at the same time as the case)
using incidence sampling. Three controls per case were
selected to maximise statistical efficiency [13]. The index
date of the controls was set to be that of the case (i.e.
the start of the exacerbation episode). Controls with any
record of exacerbation in primary care, or in HES in the
primary diagnosis field, in the period six months prior to
and three months post the index date of the case, were
excluded. Each patient could only be a matched control
for one case.
Statistical analysis
Characteristics of both study cohorts were described
using counts and percentages. Characteristics identified
at the index date in the primary care data included age,
sex, socio-economic status, BMI category (<20 under-
weight, 20–< 25 healthy weight, 25–< 30 overweight, 30+
obese), smoking status, prescriptions in the previous
three months of any antibiotic, oral glucocorticoid ther-
apy or anticholinergics (ipratropium bromide and
tiotropium only), medical history of hypertension, dia-
betes, heart failure and depression, and most recent
measure of forced expiratory volume in one second
(FEV1 as classified by the Global initiative for Obstruct-
ive Lung Disease (GOLD) scale [14]).
For cohort 2, the characteristics listed above were
compared between exacerbation cases and their matched
controls using conditional logistic regression. A “missing
value” category was assigned to categorical variables to
enable the comparison of the proportion of missing data
between exacerbation cases and their matched controls.
Analysis of cohort 2: exacerbation cases
Resource utilisation on the exacerbation date, and in the
week and three month period preceding it, was evalu-
ated for the cases. This included prescribing of any anti-
biotic or oral corticosteroid, referrals to A&E units and
community respiratory teams (as defined by Read codes
and the NHS speciality recorded by the GP), hospitalisa-
tion with exacerbation as a primary diagnosis (as
recorded in HES) with and without intubation or mech-
anical ventilation, lower respiratory tract infection, puru-
lent sputum, increased sputum volume and increased
dyspnoea.
Incidence rates of repeat exacerbation and all cause
mortality in the three months following the exacerbation
were calculated, stratified by the GOLD severity scale.
The risk of repeat exacerbation and all mortality by
GOLD severity was modelled using Cox regression,
adjusting for age and gender. For both the incidence
rates and the Cox regression follow-up time was cen-
sored at the end of data collection for each patient (i.e.
the minimum of the date at which the patient left the
practice and the last CPRD collection date from that
practice).
The proportion of exacerbation cases prescribed an
antibiotic on the index date was assessed by GP practice.
The practice prescribing rate was plotted against the
number of exacerbation cases, and confidence limits of
the overall prescribing rate ±3 standard errors were
superimposed. Prescribing variability was evaluated
using a multilevel random intercept logistic model, with
patients (level 1) clustered within practices (level 2),
adjusting for patient characteristics known to be associ-
ated with antibiotic prescribing. The significance of the
practice variation was assessed using a likelihood ratio
test comparing the multilevel random intercept logistic
model with a standard one level logistic regression
model that did not take account of clustering within
practice.
Results
Cohort 1: COPD population
The COPD cohort included 62,747 patients; half were
aged ≥70 (52%) and half were male (Table 1). Half came
from the two most deprived quintiles of the Index of
Multiple Deprivation (51%), indicating relatively low so-
cioeconomic status. The majority of patients were either
current smokers (40%) or ex-smokers (49%) and half
were overweight or obese (51%). High proportions of pa-
tients had been prescribed antibiotics (38%), anticholin-
ergics (34%) or oral glucocorticoid therapies (17%) in the
previous three months. Comorbidities were frequently
recorded: 39% had a prior record of hypertension, 29%
had a record of depression, 13% had a record of dia-
betes, and 8% had a record of heart failure. Just under
half of patients were known to have severe (32%) or very
severe COPD (13%).
Cohort 2: exacerbation cases and controls
Within the study population, 12,609 patients were iden-
tified as having had an exacerbation episode; these cases
were matched by age and gender to up to three controls
each, resulting in 35,299 controls. Exacerbations were in-
versely associated with affluence (most affluent quintile
compared to median quintile, matched odds ratio (OR) =
0.81 [95%CI 0.75–0.87]) and positively associated with
being underweight (compared to healthy weight, OR =
1.13 [95%CI 1.06–1.21]) and current or past smoking
(compared to non-smoking, OR = 1.42 [95%CI 1.30–
1.55] and 1.38 [95%CI 1.27–1.50] respectively) (Table 2).
Exacerbations were inversely associated with hyperten-
sion (OR 0.93 [95%CI 0.89–0.97]) and diabetes (OR
0.94 [95%CI 0.89–0.99]), and positively associated with
depression (OR 1.17 [95%CI 12–1.22]). A higher pro-
portion of cases had recently been prescribed oral
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glucocorticoid therapies (34%, OR 2.57 [95%CI 2.45–
2.69]), anticholinergics (64%, OR 1.99 [1.91–2.08]) and
antibiotics (51%, OR 1.95 [95%CI 1.87–2.03]) compared
to the controls. In addition, 40% of cases were known
to have severe or very severe COPD, compared to 27%
of controls (very severe compared to mild COPD OR
2.12 [95%CI 1.95–2.32], severe compared to mild
COPD OR 1.61 [95%CI 1.51–1.72]).
Cohort 2: exacerbation cases
Table 3 shows the characteristics of exacerbation cases.
A large number were prescribed an antibiotic (61%) or
an oral corticosteroid (51%) on the date of the exacerba-
tion record (70% of patients received either or both).
The majority of exacerbations were managed in the pri-
mary care setting, as only 10% were referred to A&E,
and only 7% were admitted to hospital for the COPD ex-
acerbation, in the 7 days prior to and including the date
of the exacerbation record.
The incidence rates of repeat exacerbation and all
cause mortality were 13.0 and 6.1 per 10,000 person-
years, respectively (Table 4). After adjustment for age
and sex, the risk of outcomes was seen to be highest
amongst patients with very severe COPD.
Whilst 61% of exacerbation cases were prescribed anti-
biotics, this proportion varied considerably between the
237 GP practices (interquartile range, 48–73%). In the
92 practices with at least 50 COPD patients, the propor-
tion varied between 29% and 88% (interquartile range,
56–74%). Figure 1 shows a large proportion (25%) of GP
practices with a prescribing rate outside that which
might be expected, as indicated by their location outside
of the confidence limits. GP practice explained 15%
(95%CI, 12–19%) of the variability in antibiotic prescrib-
ing, after adjustment for patient characteristics (COPD
hospitalisation, increased dyspnoea, age 80+, recent pre-
scribing of oral glucocorticoid therapy or antibiotics,
COPD severity, heart failure, underweight; all found to
be inversely associated with antibiotic prescribing). The
likelihood ratio test, comparing models with or without
GP practice as a level, confirmed that clustering by GP
practice was statistically significant (p < 0.001).
Discussion
Summary of main findings
This study of linked primary and secondary care data-
bases provides an important perspective on the manage-
ment and outcomes of COPD exacerbations. The results
show that patients with an exacerbation recorded have
higher recent prescribing rates (of oral glucocorticoid
therapies, anticholinergics and antibiotics), and crucially,
more severe COPD as measured by FEV1, which is
shown to be associated with repeat exacerbation and all
cause mortality. Whilst the majority of exacerbations are
Table 1 Characteristics of the COPD population,
measured at the random index date
Characteristic COPD
population
62,747 (%)
Age at random index date
40–49 2,734 (4.4%)
50–59 9,253 (14.7%)
60–69 18,203 (29.0%)
70–79 19,615 (31.3%)
80+ 12,942 (20.6%)
Male 33,241 (53.0%)
Quintile of Index of Multiple Deprivation
0 (least deprived) 7,153 (11.4%)
1 11,199 (17.8%)
2 12,441 (19.8%)
3 14,801 (23.6%)
4 (most deprived) 17,033 (27.1%)
Body mass index at random index date
Underweight 6,109 (9.7%)
Normal 18,556 (29.6%)
Overweight 18,640 (29.7%)
Obese 13,224 (21.1%)
Unknown 6,218 (9.9%)
Smoking status at random index date
Non Smoker 6,586 (10.5%)
Ex Smoker 30,494 (48.6%)
Smoker 24,849 (39.6%)
Unknown 818 (1.3%)
Prescriptions in the previous three months
Antibiotics 23,740 (37.8%)
Oral glucocorticoid therapies 10,645 (17.0%)
Anticholinergics 21,104 (33.6%)
Medical history
Hypertension 24,245 (38.6%)
Diabetes 8,322 (13.3%)
Heart Failure 5,132 (8.2%)
Depression 18,282 (29.1%)
Forced expiratory volume in one second (FEV1) as
proportion of predicted
Mild COPD (≥80) 2,699 (4.3%)
Moderate COPD (50–<80%) 10,434 (16.6%)
Severe COPD (30–< 50%) 20,283 (32.3%)
Very severe COPD (<30%) 8,095 (12.9%)
Unknown 21,236 (33.8%)
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managed by GPs, there is significant variation between
GP practices in the proportion of patients who receive a
prescription for an antibiotic, which cannot be explained
by patient characteristics alone.
Strengths and limitations of the study
The large scale of the CPRD primary care database
allowed analysis both at the patient and practice level.
Table 3 Characteristics of the COPD exacerbation cases
N (%)
(total number of
cases = 12,609)
Characteristic
Purulent sputum:
On index date 171 (1.4%)
7 days prior to index - index date 230 (1.8%)
Lower respiratory infection:
On index date 272 (2.2%)
7 days prior to index - index date 578 (4.6%)
90 days prior to index - index date 2,462 (19.5%)
Antibiotic prescribing:
On index date 7,705 (61.1%)
7 days prior to index - index date 8,346 (66.2%)
90 days prior to index - index date 10,452 (82.9%)
90 days prior to index – 1 day before index 2,747 (21.8%)
Oral corticosteroid prescribing:
On index date 6,444 (51.1%)
7 days prior to index - index date 6,869 (54.5%)
90 days prior to index - index date 8,511 (67.5%)
Referral to community respiratory team:
7 days prior to index - index date 6 (<0.1%)
Referral to Accident and Emergency:
On index date 888 (7.0%)
7 days prior to index - index date 1,239 (9.8%)
Hospitalisations for COPD exacerbation:
7 days prior to index - index date 832 (6.6%)
With intubation or mechanical ventilation 33 (0.3%)
Table 2 Predictors of COPD exacerbations
Characteristic Exacerbation
Cases
Controls Unadjusted
matched
12,609 (%) 35,299 (%) OR (95% CI)
Age at exacerbation
40–49 340 (2.7%) 985 (2.8%)
50–59 1,473 (11.7%) 4,120 (11.7%)
60–69 3,548 (28.1%) 9,831 (27.9%)
70–79 4,399 (34.9%) 12,210 (34.6%)
80+ 2,849 (22.6%) 8,153 (23.1%)
Male 6,240 (49.5%) 17,604 (49.9%)
Quintile of Index of
Multiple Deprivation
0 (least deprived) 1,358 (10.8%) 4,564 (12.9%) 0.81 (0.75–0.87)
1 2,033 (16.1%) 5,964 (16.9%) 0.92 (0.86–0.99)
2 2,585 (20.5%) 7,022 (19.9%) 1.00
3 2,659 (21.1%) 7,479 (21.2%) 0.97 (0.91–1.03)
4 (most deprived) 3,974 (31.5%) 10,270 (29.1%) 1.05 (0.99–1.11)
Body mass index at
exacerbation
Underweight 1,562 (12.4%) 3,795 (10.8%) 1.13 (1.06–1.21)
Normal 3,846 (30.5%) 10,610 (30.1%) 1.00
Overweight 3,747 (29.7%) 10,747 (30.4%) 0.96 (0.91–1.01)
Obese 2,856 (22.7%) 8,295 (23.5%) 0.95 (0.90–1.01)
Unknown 598 (4.7%) 1,852 (5.2%) 0.89 (0.81–0.99)
Smoking status at
exacerbation
Non Smoker 840 (6.7%) 3,171 (9.0%) 1.00
Ex Smoker 7,141 (56.6%) 19,618 (55.6%) 1.38 (1.27–1.50)
Smoker 4,600 (36.5%) 12,414 (35.2%) 1.42 (1.30–1.55)
Unknown 28 (0.2%) 96 (0.3%) 1.12 (0.73–1.72)
Prescriptions in the
previous three
months
Antibiotics 6,403 (50.8%) 12,193 (34.5%) 1.95 (1.87–2.03)
Oral
glucocorticoid
therapies
4,270 (33.9%) 5,871 (16.6%) 2.57 (2.45–2.69)
Anticholinergics 8,092 (64.2%) 16,738 (47.4%) 1.99 (1.91–2.08)
Medical history
Hypertension 5,216 (41.4%) 15,163 (43.0%) 0.93 (0.89–0.97)
Diabetes 2,047 (16.2%) 6,028 (17.1%) 0.94 (0.89–0.99)
Heart Failure 1,314 (10.4%) 3,476 (9.8%) 1.07 (1.00–1.15)
Depression 4,624 (36.7%) 11,717 (33.2%) 1.17 (1.12–1.22)
Forced expiratory
volume in one
second (FEV1) as
proportion of
predicted
Mild COPD (≥80) 1,832 (14.5%) 6,102 (17.3%) 1.00
Table 2 Predictors of COPD exacerbations (Continued)
Moderate COPD
(50–<80%)
4,245 (33.7%) 13,838 (39.2%) 1.03 (0.96–1.09)
Severe COPD
(30–<50%)
3,625 (28.7%) 7,533 (21.3%) 1.61 (1.51–1.72)
Very severe COPD
(<30%)
1,362 (10.8%) 2,146 (6.1%) 2.12 (1.95–2.32)
Unknown 1,545 (12.3%) 5,680 (16.1%) 0.88 (0.82–0.96)
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The representativeness and high quality of the database
has been shown previously, indicating results are likely
to be generalisable to England as a whole [9-11]. In
addition, the linkage of primary care to secondary care
data allowed for a broader analysis of resource utilisa-
tion, including whether patients received intubation or
mechanical ventilation. However, some variables associ-
ated with antibiotic prescribing were not available, for
example, nutritional status, certain biomarkers, and GP
characteristics.
FEV1 was unknown for approximately 12% of exacer-
bation cases, and 34% of the COPD population overall.
Whilst further FEV1 data may be recorded in the free
text of the primary care data, which was not used in this
study, prospective studies may wish to consider provid-
ing patients with spirometry devices to allow them to
Table 4 Outcomes (repeat COPD exacerbation and mortality) in the three months following COPD exacerbation by
FEV1
Outcome FEV1
severity
Number of events
(numerator)
Incidence rate per 10,000 person
years
Age and sex adjusted hazard
ratio
Repeat COPD
exacerbation
Mild 123 12.2 (10.2–14.5) 1.00
Moderate 256 10.9 (9.6–12.3) 0.90 (0.72–1.11)
Severe 287 14.6 (13.0–16.4) 1.22 (0.99–1.51)
Very severe 129 17.8 (15.0–21.2) 1.51 (1.18–1.94)
Unknown 103 12.4 (10.2–15.0) 1.01 (0.78–1.32)
All cause mortality Mild 75 4.9 (3.9–6.1) 1.00
Moderate 103 2.9 (2.4–3.5) 0.60 (0.45–0.81)
Severe 192 6.4 (5.5–7.4) 1.26 (0.97–1.65)
Very severe 107 9.6 (8.0–11.6) 2.14 (1.59–2.88)
Unknown 166 13.2 (11.3–15.3) 2.23 (1.69–2.93)
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Figure 1 Variability of GP practice prescribing rates of antibiotics to COPD exacerbation cases with superimposed confidence limits
(±3 standard errors) for all 237 practices with at least one case.
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record their own measurements over time. However, in
those patients with FEV1 measurements recorded by
their GP, a clear relationship was seen between severity
and poor outcomes, including exacerbations and mortal-
ity. This is in line with a recent review that found FEV1
a consistently strong predictor of exacerbation, hospital-
isation and mortality amongst patients with COPD [15].
Despite purulent sputum being a commonly reported
symptom of exacerbation, only a very small proportion
of cases had this recorded by their GP [3]. Prospective
studies should encourage GPs to record whether sputum
is purulent or not, to enable a more robust analysis of
the relationship with prescribing and outcomes.
This study was restricted to antibiotic prescriptions
given by GPs, with the main analysis focusing on pre-
scriptions on the exacerbation index date. This would
not have captured prescriptions given on hospital dis-
charge, provided in outpatient or home care settings, or
those previously “stockpiled” by the patient.
Comparison with existing literature
The significant variation between practices in antibiotic
prescribing rates described in this study is consistent
with the Audit Commission report of GP prescribing be-
haviours [16]. Prescribing rates are driven by a range of
factors including physician’s knowledge, experience and
uncertainty, time pressures, and varied approach to the
role of patients in decision-making [17,18]. Conversely, a
cohort study investigating the total number of prescrip-
tions given to a patient by their GP found that most of
the practice level variation could be explained by the pa-
tient’s age, sex and morbidity [19]. However, studies fo-
cusing specifically on antibiotic prescribing rates have
demonstrated wide variation between practitioners that
cannot be explained by differences in the epidemiology
of infections, populations, or case mix, both in the UK
and around the world [20-25].
Conclusions
This study supports the need for a randomised trial to
establish the role of antibiotics in treating mild or mod-
erate COPD exacerbation, and ensure prescribing is evi-
dence based rather than reliant on prescriber preference.
A pragmatic trial using routinely collected EHR data ap-
pears feasible, as the COPD patients with exacerbation
records were demographically representative of the
COPD population overall, and disease severity recorded
by the GP was strongly associated with both exacerba-
tions and mortality.
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